Raymond James Financial
AYTU icon

Raymond James Financial’s AYTU BioPharma AYTU Stock Holding History

Raymond James Financial’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-55
Closed -$120 – 5112
2025
Q2 		$120 Buy
+55
New +$85 ﹤0.01% 6825

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Raymond James Financial's AYTU Position: Q3 2025 in Review

Raymond James Financial sold out of AYTU BioPharma (AYTU) in Q3 2025, closing a stake of 55 shares — an estimated $120 sold.

Raymond James Financial first reported a position in AYTU in Q2 2025 and held it in 1 quarter. The position peaked at $120 in Q2 2025. 33 funds tracked by Wall St. Rank hold AYTU as of Q3 2025.

  • Raymond James Financial reported no remaining AYTU BioPharma position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 55 AYTU BioPharma shares in Q3 2025, an estimated $120.
  • Raymond James Financial first reported a position in AYTU BioPharma in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's AYTU BioPharma position peaked at $120 in Q2 2025.
  • 33 funds tracked by Wall St. Rank held AYTU BioPharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.